Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
RESEARCH TOOLSreports
Holding BLTE?
Track your performance easily
Earnings Data
Report Date
Mar 28, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.33Last Year’s EPS
-$0.25Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 12, 2024
|% Change Since: -18.46%
|Next Earnings Date:Mar 28, 2025
Earnings Call Sentiment|Positive
The earnings call conveyed optimism with significant progress in clinical trials, regulatory designations, and financial stability. However, challenges such as adverse events in trials and a notable net loss were also acknowledged.Company Guidance
During Belite Bio's third-quarter 2024 earnings call, the company provided detailed guidance on their ongoing clinical trials and financial performance. They are advancing Tinlarebant, a novel oral therapy for Stargardt disease and geographic atrophy, which has received rare pediatric disease and Fast Track designations in the U.S., as well as Orphan Drug designation in the U.S., EU, and Japan. The Phase III DRAGON trial for Stargardt disease aims to enroll 60 subjects, while the Phase II/III DRAGON 2 trial is fully enrolled with 104 patients, and the Phase III PHOENIX trial for geographic atrophy targets 429 subjects, having already enrolled over 280. Financially, Belite reported R&D expenses of $6.8 million and a net loss of $8.7 million for Q3 2024, with $109 million in cash reserves, ensuring a four-year cash runway to achieve key milestones.Leadership Addition
Dr. Hendrik Scholl, a leading expert in Stargardt disease and age-related macular degeneration, joined as Chief Medical Officer, bringing significant expertise to the clinical program.
Progress in Clinical Trials
The DRAGON 2 trial for Stargardt's disease is fully enrolled with 104 patients, and the PHOENIX trial for geographic atrophy has enrolled over 280 subjects. There is also progress in dosing and enrollment in the U.S., U.K., and Japan.
Significant Clinical Trial Results
The Phase II study with Tinlarebant showed a significant reduction in the growth rate of Stargardt disease lesions and stabilization of visual acuity loss.
Financial Position
R&D expenses decreased to $6.8 million from $8.7 million year-over-year. The company maintains a strong balance sheet with $109 million in cash, providing about 4 years of cash runway.
Regulatory Designations
Tinlarebant has received rare pediatric disease and Fast Track designations in the U.S., and Orphan Drug designation in the U.S., EU, and Japan, highlighting significant unmet medical needs.
---
BLTE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLTE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $78.64 | $81.15 | +3.19% |
| Aug 09, 2024 | $49.48 | $48.55 | -1.88% |
| May 14, 2024 | $41.68 | $42.00 | +0.77% |
| Mar 12, 2024 | $44.60 | $39.04 | -12.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Belite Bio, Inc. ADR (BLTE) report earnings?
Belite Bio, Inc. ADR (BLTE) is schdueled to report earning on Mar 28, 2025, TBA Not Confirmed.
What is Belite Bio, Inc. ADR (BLTE) earnings time?
Belite Bio, Inc. ADR (BLTE) earnings time is at Mar 28, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLTE EPS forecast?
BLTE EPS forecast for the fiscal quarter 2024 (Q4) is -$0.33.
---